Dr. Ferdinando Calabria graduated with a degree in Medicine in 2005 and specialized in Nuclear Medicine in 2009 at the University of Rome “Tor Vergata.” His specific scientific interest is in deepening our knowledge of the physio-pathological features of PET radiopharmaceuticals bio-distribution in order to verify further diagnostic applications. Another topic is the evaluation of the potential added value of hybrid imaging with SPECT/CT and PET/CT scanners. Since 2010, he has been researcher, focusing the attention on prostate cancer imaging with PET/CT and  potential applications of PET/MRI in neurology and neuro-oncology, particularly at the Italian National Research Council, using a multidisciplinary network approach. He is currently exploring the role of advanced hybrid imaging with SPECT/CT and PET/CT in oncology and neurology, at the national public Hospital “Mariano Santo” in Cosenza, Italy. The author of over 50 scientific papers listed in PubMed, he has also served as a reviewer for the major specialized scientific journals of nuclear medicine and radiology. Prof. Orazio Schillaci graduated with a degree in Medicine in 1990 and specialized in Nuclear Medicine in 19942 at the University of Rome “La Sapienza.” He began his scientific work at the University of L’Aquila: during this important period, Schillaci started exploring molecular imaging, with an emphasis on SPECT for neuroendocrine tumors. After a research stay in California, USA, he became a Professor of Nuclear Medicine at the University of Rome “Tor Vergata” in 2001. Since 2008 he has led the School of Specialization in Nuclear Medicine and, since 2013, has been Director of the School Of Medicine at the “Tor Vergata” University Hospital in Rome. The author of more than 220 scientific articles listed in PubMed, his current research interest is in the development of novel PET radiopharmaceuticals and their potential clinical applications in oncology,neurology, cardiology and infectious disease, within a network involving several Italian and European institutions. He is also the former President of the Italian Association of Nuclear Medicine.

"The volume of 330 pages enriched by more than 200 images, is organized … . The original approach makes the publication interesting also for those who already practice the discipline as well as for all those culturally or professionally interested in the premises and applications of nuclear medicine." (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 52 (2), 2025)

• 1. 18F-FDG.- 2. 18F-DOPA.- 3. The lipogenesis pathway: radiolabeled Choline.- 4. 18F-FET.- 5. 18F-NaF.- 6. Somatostatin receptor analogs (68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-DOTATATE).- 7.  7 64Cu-Radiopharmaceuticals.- 8. Amyloid Imaging.- 9. PET myocardial perfusion imaging: 82Rb.- 10. The Bone Pathway: 223Ra-Dichloride.- 11. 11C-Methionine.- 12. 68Ga-PSMA.- 13. PET biomarkers for Tau Pathology.- 14. 18F-Fluciclovine.- 15. 18F-FAPI.- 16. 18F-FES.- 17. 68Ga-Pentixafor.- 18. 18F-FLT.- 19. Neuroinflammation.- 20. 18F-FAZA.

Dr. Ferdinando Calabria graduated with a degree in Medicine in 2005 and specialized in Nuclear Medicine in 2009 at the University of Rome “Tor Vergata.” His specific scientific interest is in deepening our knowledge of the physio-pathological features of PET radiopharmaceuticals bio-distribution in order to verify further diagnostic applications. Another topic is the evaluation of the potential added value of hybrid imaging with SPECT/CT and PET/CT scanners. Since 2010, he has been researcher, focusing the attention on prostate cancer imaging with PET/CT and  potential applications of PET/MRI in neurology and neuro-oncology, particularly at the Italian National Research Council, using a multidisciplinary network approach. He is currently exploring the role of advanced hybrid imaging with SPECT/CT and PET/CT in oncology and neurology, at the national public Hospital “Mariano Santo” in Cosenza, Italy. The author of over 50 scientific papers listed in PubMed, he has also served as a reviewer for the major specialized scientific journals of nuclear medicine and radiology. Prof. Orazio Schillaci graduated with a degree in Medicine in 1990 and specialized in Nuclear Medicine in 19942 at the University of Rome “La Sapienza.” He began his scientific work at the University of L’Aquila: during this important period, Schillaci started exploring molecular imaging, with an emphasis on SPECT for neuroendocrine tumors. After a research stay in California, USA, he became a Professor of Nuclear Medicine at the University of Rome “Tor Vergata” in 2001. Since 2008 he has led the School of Specialization in Nuclear Medicine and, since 2013, has been Director of the School Of Medicine at the “Tor Vergata” University Hospital in Rome. The author of more than 220 scientific articles listed in PubMed, his current research interest is in the development of novel PET radiopharmaceuticals and their potential clinical applications in oncology,neurology, cardiology and infectious disease, within a network involving several Italian and European institutions. He is also the former President of the Italian Association of Nuclear Medicine.

"The volume of 330 pages enriched by more than 200 images, is organized … . The original approach makes the publication interesting also for those who already practice the discipline as well as for all those culturally or professionally interested in the premises and applications of nuclear medicine." (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 52 (2), 2025)

• 1. 18F-FDG.- 2. 18F-DOPA.- 3. The lipogenesis pathway: radiolabeled Choline.- 4. 18F-FET.- 5. 18F-NaF.- 6. Somatostatin receptor analogs (68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-DOTATATE).- 7.  7 64Cu-Radiopharmaceuticals.- 8. Amyloid Imaging.- 9. PET myocardial perfusion imaging: 82Rb.- 10. The Bone Pathway: 223Ra-Dichloride.- 11. 11C-Methionine.- 12. 68Ga-PSMA.- 13. PET biomarkers for Tau Pathology.- 14. 18F-Fluciclovine.- 15. 18F-FAPI.- 16. 18F-FES.- 17. 68Ga-Pentixafor.- 18. 18F-FLT.- 19. Neuroinflammation.- 20. 18F-FAZA.

Dr. Ferdinando Calabria graduated with a degree in Medicine in 2005 and specialized in Nuclear Medicine in 2009 at the University of Rome “Tor Vergata.” His specific scientific interest is in deepening our knowledge of the physio-pathological features of PET radiopharmaceuticals bio-distribution in order to verify further diagnostic applications. Another topic is the evaluation of the potential added value of hybrid imaging with SPECT/CT and PET/CT scanners. Since 2010, he has been researcher, focusing the attention on prostate cancer imaging with PET/CT and  potential applications of PET/MRI in neurology and neuro-oncology, particularly at the Italian National Research Council, using a multidisciplinary network approach. He is currently exploring the role of advanced hybrid imaging with SPECT/CT and PET/CT in oncology and neurology, at the national public Hospital “Mariano Santo” in Cosenza, Italy. The author of over 50 scientific papers listed in PubMed, he has also served as a reviewer for the major specialized scientific journals of nuclear medicine and radiology. Prof. Orazio Schillaci graduated with a degree in Medicine in 1990 and specialized in Nuclear Medicine in 19942 at the University of Rome “La Sapienza.” He began his scientific work at the University of L’Aquila: during this important period, Schillaci started exploring molecular imaging, with an emphasis on SPECT for neuroendocrine tumors. After a research stay in California, USA, he became a Professor of Nuclear Medicine at the University of Rome “Tor Vergata” in 2001. Since 2008 he has led the School of Specialization in Nuclear Medicine and, since 2013, has been Director of the School Of Medicine at the “Tor Vergata” University Hospital in Rome. The author of more than 220 scientific articles listed in PubMed, his current research interest is in the development of novel PET radiopharmaceuticals and their potential clinical applications in oncology,neurology, cardiology and infectious disease, within a network involving several Italian and European institutions. He is also the former President of the Italian Association of Nuclear Medicine.

"The volume of 330 pages enriched by more than 200 images, is organized … . The original approach makes the publication interesting also for those who already practice the discipline as well as for all those culturally or professionally interested in the premises and applications of nuclear medicine." (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 52 (2), 2025)

• 1. 18F-FDG.- 2. 18F-DOPA.- 3. The lipogenesis pathway: radiolabeled Choline.- 4. 18F-FET.- 5. 18F-NaF.- 6. Somatostatin receptor analogs (68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-DOTATATE).- 7.  7 64Cu-Radiopharmaceuticals.- 8. Amyloid Imaging.- 9. PET myocardial perfusion imaging: 82Rb.- 10. The Bone Pathway: 223Ra-Dichloride.- 11. 11C-Methionine.- 12. 68Ga-PSMA.- 13. PET biomarkers for Tau Pathology.- 14. 18F-Fluciclovine.- 15. 18F-FAPI.- 16. 18F-FES.- 17. 68Ga-Pentixafor.- 18. 18F-FLT.- 19. Neuroinflammation.- 20. 18F-FAZA.